

Sergey Zyryanov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5434034/publications.pdf>

Version: 2024-02-01

49
papers

139
citations

1478280

6
h-index

1372474

10
g-index

64
all docs

64
docs citations

64
times ranked

131
citing authors

#	ARTICLE	IF	CITATIONS
1	The economic side of an oral sugar lowering therapy intensification by glucagon-like peptid-1 receptor agonists. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2022, , 4-15.	0.2	0
2	Pharmacokinetic analysis of meropenem therapeutic drug monitoring data (TDM) in critically ill adult patients. <i>Antibiotiki i Khimioterapiya</i> , 2022, 66, 31-38.	0.1	0
3	Consensus expert opinion on key items in planning and designing clinical trials in geriatric patients. <i>Russian Journal of Geriatric Medicine</i> , 2022, , 398-402.	0.3	0
4	Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator "reduction of mortality from diseases of the circulatory system" in 2022-2024. <i>Russian Journal of Cardiology</i> , 2022, 26, 4819.	0.4	2
5	Guidelines of the Association of Anesthesiologists-Intensivists, the Interregional Non-Governmental Organization Alliance of Clinical Chemotherapists and Microbiologists, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and NGO Russian Sepsis Forum "Diagnostics and antimicrobial therapy of the infections caused by multiresistant microorganisms" (update 2022). <i>Messenger of Anesthesiology and Resuscitation</i> , 2022, 19, 84-114.	0.1	17
6	Comparative genome analysis of global and Russian strains of community-acquired methicillin-resistant <i>Staphylococcus aureus</i> ST22, a "Gaza clone"™. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106264.	1.1	9
7	The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, , 4-14.	0.2	3
8	Multivariable Analysis of Primary Care Physician Adherence to Guideline-recommended Pharmacotherapy of Stable Coronary Artery Disease. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 29-35.	0.3	1
9	Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, 20, 4-15.	0.2	1
10	Predicting of fentanyl-associated neurotoxicity in pancreatic cancer with clical, genetic model. <i>Ekspiermental'naya i Klinicheskaya Gastroenterologiya</i> , 2021, , 136-145.	0.1	0
11	Adherence to Medical Treatment in Elderly Patients with Coronary Artery Disease in the Settings of Primary Outpatient Care. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 178-185.	0.3	4
12	Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price. <i>Farmakoeconomika</i> , 2021, 14, 103-114.	0.4	1
13	Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, , 4-15.	0.2	0
14	Rehabilitation after COVID-19. Resolution of the International Expert Council of the Eurasian Association of Therapists and the Russian Society of Cardiology. <i>Russian Journal of Cardiology</i> , 2021, 26, 4694.	0.4	9
15	Analysis of Adverse Reactions in Elderly Patients Based on Quantitative Methods of Signal Detection. <i>Safety and Risk of Pharmacotherapy</i> , 2021, 9, 144-153.	0.1	3
16	Arterial hypertension: modern advances in metabolomics. <i>Meditinskiy Sovet</i> , 2021, , 10-22.	0.1	0
17	Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer. <i>Farmakoeconomika</i> , 2021, 14, 281-290.	0.4	1
18	Treatment of epilepsy associated with primary and metastatic brain tumors. <i>Epilepsy and Paroxysmal Conditions</i> , 2021, 13, 286-304.	0.2	2

#	ARTICLE	IF	CITATIONS
19	Efficacy of azoximer bromide in the treatment of hospitalized patients with moderate to severe community-acquired pneumonia. <i>Meditinskiy Sovet</i> , 2021, , 106-117.	0.1	2
20	Generic drugs: benefit/risk ratio. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2021, 13, 98-104.	0.2	1
21	The fixed combination of diclofenac and orphenadrine in the treatment of acute pain syndromes. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2020, 12, 100-104.	0.2	5
22	Comparative pharmacoeconomic analysis of medication for patients after acute decompensated heart failure. <i>Russian Journal of Cardiology</i> , 2020, 25, 65-71.	0.4	2
23	Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation. <i>Farmakoekonomika</i> , 2020, 12, 268-278.	0.4	2
24	Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype. <i>Pulmonologiya</i> , 2020, 30, 227-244.	0.2	11
25	Guidelines of the Association of Anesthesiologists-Intensivists, the Interregional Non-Governmental Organization Alliance of Clinical Chemotherapists and Microbiologists, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and NGO Russian Sepsis Forum Diagnostics and antimicrobial therapy of the infections caused by multiresistant microorganisms. <i>Messenger of Anesthesiology and Resuscitation</i> , 2020, 16, 52-63.	0.1	21
26	Determination of the Effectiveness of Antibiotic Therapy by Conducting Therapeutic Drug Monitoring. <i>Antibiotiki i Khimioterapiya</i> , 2020, 65, 29-33.	0.1	2
27	Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 4-14.	0.2	1
28	Efficiency and safety of opioid therapy of chronic pain syndrome in patients with cancer of the refractory iron: clinico-pathogenetic features. <i>Eksperimental'naya i Klinicheskaya Gastroenterologiya</i> , 2020, 1, 45-51.	0.1	0
29	Effects of ticagrelor in patients with acute coronary syndrome on the targets of the national cardiovascular program. <i>Russian Journal of Cardiology</i> , 2020, 25, 3931.	0.4	4
30	Inhalation antibacterial drugs: current opportunities for use in respiratory infections. <i>Pulmonologiya</i> , 2020, 30, 320-328.	0.2	0
31	Effect of ticagrelor in patients with acute coronary syndrome on the achievement of the targets of federal project on the prevention of cardiovascular diseases: 3-year perspective estimates. <i>Russian Journal of Cardiology</i> , 2020, 25, 4223.	0.4	0
32	PERSONALIZED CALCULATOR FOR PREDICTION OF OPIOID-ASSOCIATED PHARMACORESISTANCE IN PATIENTS WITH PANCREAS CANCER. <i>Archiv Euromedica</i> , 2020, 10, 20-22.	0.1	1
33	PERSONALIZED CHOICE OF OPIOID THERAPY IN A PATIENT WITH CHRONIC PAIN SYNDROME ON THE BACKGROUND OF PANCREAS CANCER: CLINICAL CASE REPORT. <i>Archiv Euromedica</i> , 2020, 10, 83-85.	0.1	0
34	Drug adjustment of modified risk factors as one of the leading strategies for managing patients with cardiovascular diseases. <i>Meditinskiy Sovet</i> , 2020, , 22-38.	0.1	0
35	Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy. <i>Farmakoekonomika</i> , 2020, 13, 5-12.	0.4	1
36	Economic challenges of oncological diseasesâ€™ pharmacotherapy. <i>Farmakoekonomika</i> , 2020, 13, 64-70.	0.4	1

#	ARTICLE	IF	CITATIONS
37	harmacoeconomic feasibility of using the drug upadacitinib in patients with rheumatoid arthritis in the healthcare system of the Russian Federation. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 40-51.	0.2	0
38	Implementation of the concept of standard operating procedures into primary care practice: utopia or urgent need?. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 75-84.	0.2	1
39	Lipid-lowering therapy in patients with coronary artery disease in primary care practices: what has changed over 7 years?. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 2609.	0.4	2
40	Lipid-lowering therapy in outpatients of different ages with coronary artery disease. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 2654.	0.4	1
41	Safety and tolerability of nsaids: focus on aceclofenac. <i>Meditinskiy Sovet</i> , 2019, , 110-120.	0.1	1
42	Clinico-pharmacological characteristics of opioid drug-drug interactions in cancer patients with chronic pain syndrome. <i>Siberian Journal of Oncology</i> , 2019, 17, 114-122.	0.1	0
43	Discrepancies in drug labeling texts as a cause of medication errors. <i>Vestnik Roszdravnadzora</i> , 2019, 2019, 59-62.	0.1	0
44	AGE PECULIARITIES OF PHARMACOTHERAPY WITH AMOXICILLIN PREPARATIONS IN CHILDREN WITH CYSTIC FIBROSIS. <i>Pediatrics</i> , 2019, 98, 179-188.	0.1	0
45	The pharmacokinetic of the main oral antibiotics in children with cystic fibrosis. , 2019, , .		0
46	PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 167-175.	0.3	2
47	Generic substitutions of antiepileptic drugs: Is it possible to put an end to the discussion?. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2018, 10, 75-80.	0.2	1
48	PHARMACOKINETIC AND PHARMACOGENETIC ASPECTS OF PERSONALIZED ANALGETIC THERAPY WITH FENTANIL TTS IN CLINICAL ONCOLOGY. <i>Siberian Journal of Oncology</i> , 2018, 17, 94-100.	0.1	1
49	Drug interchangeability: Clinical efficacy and safety. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2017, 9, 4-10.	0.2	6